Max Healthcare Institute Ltd (MAXHEALTH) is currently trading at 926.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Max Healthcare operates a network of tertiary and quaternary hospitals, medical centres, pathology laboratories and homecare services, with approximately 6,200 beds across 21 facilities and a major North India presence. Q2 FY27 gross revenue grew 20% year over year to ₹3,219 crore, while operating EBITDA increased 18% to ₹820 crore. Revenue growth was volume-led, with occupied bed days rising 13%, inpatient volumes increasing 12% and occupancy remaining strong at 77%. Capacity expansion is translating into operating scale: 758 beds were added over twelve months, while management approved ₹415 crore for 209 brownfield beds and separately approved ₹425 crore for 202 beds at Vaishali. Medical value travel is becoming increasingly important, with international patient revenue rising 33% year over year to ₹307 crore and representing approximately 10% of hospital revenue, supported by India’s cost competitiveness and Max’s advanced clinical capabilities. The company is broadening its healthcare ecosystem through Max Lab and Max@Home. Max Lab now serves 63-plus cities and 2,700-plus tests, while Max@Home grew 37% year over year, led by rehabilitation, physiotherapy and pathology collection services.

Over the past 52 weeks, Max Healthcare Institute Ltd has traded between a low of ₹797.00 and a high of ₹1,187.25. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Max Healthcare Institute Ltd has a market capitalization of approximately 87,015.44. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Max Healthcare Institute Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 63.03 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 87,015.44 Cr, Max Healthcare Institute Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Max Healthcare Institute Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Max Healthcare Institute Ltd is 63.03. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Max Healthcare reported profit after tax of Rs 448 crore in Q2 FY27. This was 10% higher than normalized profit after tax of Rs 406 crore in Q2 FY26, which excludes a one-time tax gain of Rs 149 crore. Reported Q2 FY26 profit after tax was Rs 554 crore including that gain.

MAX Healthcare reported ₹448 crore of network profit after tax for Q2 FY27. The presentation identifies this as a memorandum consolidation of the network P&L rather than a measure confined to the company, subsidiaries and Silos.

Max Healthcare plans to add about 145 beds across the two hospitals. The Noida programme accounts for about 85 beds and the Vaishali programme accounts for about 60 beds.

MHIL reported consolidated revenue from operations of Rs 2,569.21 crore for the quarter ended September 30, 2026. This was 20% higher than Rs 2,135.47 crore in the quarter ended September 30, 2025.